CARA:NSD-Cara Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.94

Change

+0.40 (+3.47)%

Market Cap

USD 0.64B

Volume

0.52M

Avg Analyst Target

USD 25.67 (+114.96%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Cara Therapeutics Inc (CARA) Stock Analysis:
Based on the Cara Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Cara Therapeutics Inc is USD 25.67 over the next 12 months. Cara Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cara Therapeutics Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Cara Therapeutics Inc’s stock price was USD 11.94. Cara Therapeutics Inc’s stock price has changed by +0.01% over the past week, -0.51% over the past month and -41.07% over the last year.

About

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing CARA

Symbol Name Weight Mer Price(Change) Market Cap
CNBS Amplify ETF Trust - Ampli.. 0.00 % 0.75 %

-0.33 (-2.50%)

N/A
MJX ETFMG Alternative Harvest.. 0.00 % 0.00 %

N/A

N/A
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

-0.10 (-0.98%)

N/A
FLWG:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-5.85 (-1.47%)

N/A
FLWR:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-0.09 (-1.61%)

N/A
CBSX:XETRA Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

-0.13 (-1.55%)

USD0.03B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

N/A
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.97% 83% B 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.97% 83% B 57% F
Trailing 12 Months  
Capital Gain -41.07% 62% D- 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.07% 62% D- 27% F
Trailing 5 Years  
Capital Gain 4.46% 59% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.46% 59% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 5.69% 44% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.69% 44% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 31.07% 83% B 56% F
Risk Adjusted Return 18.31% 49% F 35% F
Market Capitalization 0.64B 72% C- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.95 27% F 35% F
Price/Book Ratio 3.12 48% F 39% F
Price / Cash Flow Ratio -116.43 97% A+ 93% A
EV/EBITDA 22.05 16% F 32% F
Management Effectiveness  
Return on Equity 14.24% 96% A 78% C+
Return on Invested Capital 2.79% 86% B 59% F
Return on Assets 7.63% 96% A 88% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.54 47% F 33% F
Short Percent 3.56% 58% F 42% F
Beta 1.03 61% D- 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.